This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (385)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Psychopharmacology  • Evidence-Based Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

John M. Davis, MD; Nancy Chen, MS; Ira D. Glick, MD

Arch Gen Psychiatry. 2003;60:553-564.

Background  Consensus panel recommendations regarding choice of an antipsychotic agent for schizophrenia differ markedly, but most consider second-generation antipsychotics (SGAs) as a homogeneous group. It has been suggested that SGAs seem falsely more efficacious than first-generation antipsychotics (FGAs) as a result of reduced efficacy due to use of a high-dose comparator, haloperidol. We performed (1) a meta-analysis of randomized efficacy trials comparing SGAs and FGAs, (2) comparisons between SGAs, (3) a dose-response analysis of FGAs and SGAs, and (4) an analysis of the effect on efficacy of an overly high dose of an FGA comparator.

Methods  Literature search of clinical trials between January 1953 and May 2002 of patients with schizophrenia from electronic databases, reference lists, posters, the Food and Drug Administration, and other unpublished data. We included 124 randomized controlled trials with efficacy data on 10 SGAs vs FGAs and 18 studies of comparisons between SGAs. Two of us independently extracted the sample sizes, means, and standard deviation of the efficacy data.

Results  Using the Hedges-Olkin algorithm, the effect sizes of clozapine, amisulpride, risperidone, and olanzapine were 0.49, 0.29, 0.25, and 0.21 greater than those of FGAs, with P values of 2 x 10^-8, 3 x 10^-7, 2 x 10^-12, and 3 x 10^-9, respectively. The remaining 6 SGAs were not significantly different from FGAs, although zotepine was marginally different. No efficacy difference was detected among amisulpride, risperidone, and olanzapine. We found no evidence that the haloperidol dose (or all FGA comparators converted to haloperidol-equivalent doses) affected these results when we examined its effect by drug or in a 2-way analysis of variance model in which SGA effectiveness is entered as a second factor.

Conclusion  Some SGAs are more efficacious than FGAs, and, therefore, SGAs are not a homogeneous group.

From the Psychiatric Institute, University of Illinois at Chicago (Dr Davis and Ms Chen); and the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif (Dr Glick). This study received no direct or indirect support from the pharmaceutical industry.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses
Rajiv Tandon and Henry A. Nasrallah
Arch Gen Psychiatry. 2006;63(8):935-937.
EXTRACT | FULL TEXT  

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses—Reply
John M. Davis, Nancy Chen, and Ira D. Glick
Arch Gen Psychiatry. 2006;63(8):937-939.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antipsychotic long-acting injections: mind the gap
Patel et al.
Br. J. Psychiatry 2009;195:S1-S4.
ABSTRACT | FULL TEXT  

Single- and Multiple-Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release
Boom et al.
J Clin Pharmacol 2009;49:1318-1330.
ABSTRACT | FULL TEXT  

Gray Matter in First-Episode Schizophrenia Before and After Antipsychotic Drug Treatment. Anatomical Likelihood Estimation Meta-analyses With Sample Size Weighting
Leung et al.
Schizophr Bull 2009;0:sbp099v1-sbp099.
ABSTRACT | FULL TEXT  

Long-term treatment with flupentixol results of a post-marketing surveillance study
Messer et al.
J Psychopharmacol 2009;23:805-813.
ABSTRACT  

Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Parks et al.
Schizophr Bull 2009;35:931-936.
ABSTRACT | FULL TEXT  

Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck and Sernyak
Health Aff (Millwood) 2009;28:w782-w793.
ABSTRACT | FULL TEXT  

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder
Muller et al.
J Psychopharmacol 2009;23:278-286.
ABSTRACT  

Minimal-medication approaches to treating schizophrenia
Calton and Spandler
Adv. Psychiatr. Treat. 2009;15:209-217.
ABSTRACT | FULL TEXT  

A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Leucht et al.
Am. J. Psychiatry 2009;166:152-163.
ABSTRACT | FULL TEXT  

CATIE Findings Revisited
Davis et al.
Psychiatr. Serv. 2009;60:125-126.
FULL TEXT  

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid et al.
J Psychopharmacol 2009;23:65-73.
ABSTRACT  

Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose
Hansen et al.
Med Decis Making 2009;29:91-103.
ABSTRACT  

What Explains the Diffusion of Treatments for Mental Illness?
Drake et al.
Am. J. Psychiatry 2008;165:1385-1392.
FULL TEXT  

Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller et al.
Br. J. Psychiatry 2008;193:279-288.
ABSTRACT | FULL TEXT  

Delusional disorder, somatic type treated with aripiprazole--mirtazapine combination
Dimopoulos et al.
J Psychopharmacol 2008;22:812-814.
ABSTRACT  

Haloperidol versus chlorpromazine for treatment of schizophrenia
Leucht et al.
Schizophr Bull 2008;34:813-815.
FULL TEXT  

Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997-2002
Yang et al.
The Annals of Pharmacotherapy 2008;42:1229-1238.
ABSTRACT | FULL TEXT  

Rechallenging With Clozapine Following Neutropenia: Treatment Options for Refractory Schizophrenia
Ghaznavi et al.
Am. J. Psychiatry 2008;165:813-818.
FULL TEXT  

Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand
Wheeler
The Annals of Pharmacotherapy 2008;42:852-860.
ABSTRACT | FULL TEXT  

Introduction to the CATIE Special Section
Swartz
Psychiatr. Serv. 2008;59:497-499.
FULL TEXT  

What CATIE Found: Results From the Schizophrenia Trial
Swartz et al.
Psychiatr. Serv. 2008;59:500-506.
ABSTRACT | FULL TEXT  

Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Rosenheck et al.
Psychiatr. Serv. 2008;59:515-520.
ABSTRACT | FULL TEXT  

Lessons to Take Home From CATIE
Carpenter and Buchanan
Psychiatr. Serv. 2008;59:523-525.
ABSTRACT | FULL TEXT  

Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine
Ohlsen et al.
J Psychopharmacol 2008;22:323-329.
ABSTRACT  

Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?
Davis and Leucht
Schizophr Bull 2008;34:403-405.
FULL TEXT  

Rethinking Antipsychotic Formulary Policy
Rosenheck et al.
Schizophr Bull 2008;34:375-380.
ABSTRACT | FULL TEXT  

Unanswered Questions in Schizophrenia Clinical Trials
Kane and Leucht
Schizophr Bull 2008;34:302-309.
FULL TEXT  

Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT | FULL TEXT  

CATIE and CUtLASS: can we handle the truth?
Lewis and Lieberman
Br. J. Psychiatry 2008;192:161-163.
ABSTRACT | FULL TEXT  

How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Owens
Adv. Psychiatr. Treat. 2008;14:17-28.
ABSTRACT | FULL TEXT  

Clozapine-induced leukopenia successfully treated with lithium
Kutscher et al.
Am J Health Syst Pharm 2007;64:2027-2031.
ABSTRACT | FULL TEXT  

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck
Br. J. Psychiatry 2007;191:238-245.
ABSTRACT | FULL TEXT  

Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence
Chan and Sweeting
J Psychopharmacol 2007;21:657-664.
ABSTRACT  

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study
KEKS et al.
Br. J. Psychiatry 2007;191:131-139.
ABSTRACT | FULL TEXT  

Measurement of long-term outcomes in observational and randomised controlled trials
Hodgson et al.
Br. J. Psychiatry 2007;191:s78-s84.
ABSTRACT | FULL TEXT  

The Neuropharmacology of Psychosis
Tamminga and Davis
Schizophr Bull 2007;33:937-946.
ABSTRACT | FULL TEXT  

Pharmacogenomics in Psychiatry
Leckband et al.
Journal of Pharmacy Practice 2007;20:252-264.
ABSTRACT  

Effectiveness of antipsychotics: Is the CATIE trial a tsunami?
Stip and Anselmo
cfp 2007;53:97-98.
FULL TEXT  

Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF?
Leucht et al.
Schizophr Bull 2007;33:183-191.
ABSTRACT | FULL TEXT  

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents
Klein et al.
Am. J. Psychiatry 2006;163:2072-2079.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck et al.
Am. J. Psychiatry 2006;163:2080-2089.
ABSTRACT | FULL TEXT  

Symptom domains of schizophrenia: the role of atypical antipsychotic agents
Burton
J Psychopharmacol 2006;20:6-19.
ABSTRACT  

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses
Turner and Stewart
J Psychopharmacol 2006;20:20-37.
ABSTRACT  

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
McCUE et al.
Br. J. Psychiatry 2006;189:433-440.
ABSTRACT | FULL TEXT  

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Lieberman
Arch Gen Psychiatry 2006;63:1069-1072.
FULL TEXT  

Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Rosenheck
Arch Gen Psychiatry 2006;63:1074-1076.
FULL TEXT  

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones et al.
Arch Gen Psychiatry 2006;63:1079-1087.
ABSTRACT | FULL TEXT  

Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Lambert et al.
Am J Epidemiol 2006;164:672-681.
ABSTRACT | FULL TEXT  

Integrated Psychological Therapy (IPT) for Schizophrenia: Is It Effective?
Roder et al.
Schizophr Bull 2006;32:S81-S93.
ABSTRACT | FULL TEXT  

Bibliography PSYCHOPHARMACOLOGY
Focus 2006;4:512.
FULL TEXT  

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup et al.
Focus 2006;4:539.
FULL TEXT  

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses.
Tandon and Nasrallah
Arch Gen Psychiatry 2006;63:935-937.
FULL TEXT  

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses--Reply
Davis et al.
Arch Gen Psychiatry 2006;63:937-939.
FULL TEXT  

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
Tiihonen et al.
BMJ 2006;333:224.
ABSTRACT | FULL TEXT  

Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison.
Shaw et al.
Arch Gen Psychiatry 2006;63:721-730.
ABSTRACT | FULL TEXT  

The Potential Impact of the Recovery Movement on Family Interventions for Schizophrenia: Opportunities and Obstacles
Glynn et al.
Schizophr Bull 2006;32:451-463.
ABSTRACT | FULL TEXT  

Are older antipsychotic drugs obsolete?
Ganguli and Strassnig
BMJ 2006;332:1346-1347.
FULL TEXT  

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski et al.
Arch Gen Psychiatry 2006;63:622-629.
ABSTRACT | FULL TEXT  

Selecting antipsychotics in schizophrenia: lessons from CATIE
Haddad and Dursun
J Psychopharmacol 2006;20:332-334.
 

Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders
Bola
Research on Social Work Practice 2006;16:263-275.
ABSTRACT  

Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
Huskamp
Health Aff (Millwood) 2006;25:635-646.
ABSTRACT | FULL TEXT  

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup et al.
Am. J. Psychiatry 2006;163:611-622.
ABSTRACT | FULL TEXT  

The Choice of Drugs for Schizophrenia
Davis
NEJM 2006;354:518-520.
FULL TEXT  

Racial Disparities in the Use of Second-Generation Antipsychotics for the Treatment of Schizophrenia
Mallinger et al.
Psychiatr. Serv. 2006;57:133-136.
ABSTRACT | FULL TEXT  

Fatal Agranulocytosis 4 Years After Discontinuation of Clozapine
TIIHONEN
Am. J. Psychiatry 2006;163:161-161.
FULL TEXT  

Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia
Ezewuzie and Taylor
J Psychopharmacol 2006;20:86-90.
ABSTRACT  

Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis
Kemmler et al.
Arch Gen Psychiatry 2005;62:1305-1312.
ABSTRACT | FULL TEXT  

Weight change with atypical antipsychotics in the treatment of schizophrenia
Haddad
J Psychopharmacol 2005;19:16-27.
ABSTRACT  

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
Ascher-Svanum et al.
J Psychopharmacol 2005;19:110-117.
ABSTRACT  

Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia
Breier et al.
Am. J. Psychiatry 2005;162:1879-1887.
ABSTRACT | FULL TEXT  

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman et al.
NEJM 2005;353:1209-1223.
ABSTRACT | FULL TEXT  

The Choice of Antipsychotic Drugs for Schizophrenia
Freedman
NEJM 2005;353:1286-1288.
FULL TEXT  

Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods et al.
Arch Gen Psychiatry 2005;62:961-970.
ABSTRACT | FULL TEXT  

Modern antipsychotic drugs: a critical overview
Gardner et al.
CMAJ 2005;172:1703-1711.
ABSTRACT | FULL TEXT  

Old Versus New Medications: How Much Should Be Taught?
Jefferson
Acad. Psychiatry 2005;29:162-166.
ABSTRACT | FULL TEXT  

Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler et al.
Am. J. Psychiatry 2005;162:947-953.
ABSTRACT | FULL TEXT  

A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
Henderson et al.
Am. J. Psychiatry 2005;162:954-962.
ABSTRACT | FULL TEXT  

Medicaid Policies To Contain Psychiatric Drug Costs
Koyanagi et al.
Health Aff (Millwood) 2005;24:536-544.
ABSTRACT | FULL TEXT  

Establishing a dose-response relationship for haloperidol decanoate
Taylor
Psychiatr. Bull. 2005;29:104-107.
ABSTRACT | FULL TEXT  

Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Rosenheck
Psychiatr. Serv. 2005;56:85-92.
FULL TEXT  

Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia
Keith et al.
Psychiatr. Serv. 2004;55:997-1005.
ABSTRACT | FULL TEXT  

Diabetic Keto-Acidotic (DKA) Coma following Olanzapine Initiation in a Previously Euglycaemic Woman and Successful Continued Therapy with Olanzapine
Howes and Rifkin
J Psychopharmacol 2004;18:435-437.
ABSTRACT  

Which atypical antipsychotic for schizophrenia?
DTB 2004;42:57-60.
ABSTRACT | FULL TEXT  

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement
Citrome and Volavka
Diabetes Care 2004;27:2087-2088.
FULL TEXT  

Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia
Gilmer et al.
Am. J. Psychiatry 2004;161:692-699.
ABSTRACT | FULL TEXT  

Other articles noted: 25 Jul 03 to 7 Nov 03
Evid. Based Nurs. 2004;7:e1-1.
FULL TEXT  

Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry
Fayek et al.
Psychiatr. Serv. 2003;54:1453-1456.
FULL TEXT  

Integration of Care: Integrated Treatment of Schizophrenia
Lenroot et al.
Psychiatr. Serv. 2003;54:1499-1507.
ABSTRACT | FULL TEXT  

Are Atypical Antipsychotics Really Better Than Neuroleptics?
JWatch Psychiatry 2003;2003:1-1.
FULL TEXT  

New Studies Raise Questions About Antipsychotic Efficacy
Rosack
Psychiatr. News 2003;38:18-19.
FULL TEXT